Sanofi is planning to build a new €350m vaccines manufacturing facility at its Canadian headquarters in Toronto.
The expansion is expected to significantly bolster its paediatric and booster vaccines capacity to meet the emerging demands.
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen.
The new Toronto facility is one of the largest-ever investments by Sanofi in a single building.
Sanofi Pasteur executive vice-president and head David Loew said: “With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe.
“Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The Canadian facility is set to be completed in 2021 and will be equipped to manufacture the antigens needed for diphtheria and tetanus vaccines.
Sanofi global industrial affairs executive vice-president Philippe Luscan said: “This project is one of the most important investments for the Sanofi global industrial network.
“It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”
With more than 15 production and research and development sites, Sanofi’s vaccines business supplies one billion doses each year to tackle various infectious diseases.
It is also focused on the development of new vaccines for new infections and the enhancement of existing products to improve the well-being of patients.